Study #2021-0792
A single arm phase II study of ADjuvant Endocrine therapy, subcutaneous Pertuzumab, and Trastuzumab fixed-dose combination for patients with anatomic stage I hormone receptorpositive, HER2-positive breast cancer (ADEPT)
MD Anderson Study Status
Enrolling
Treatment Agent
Combination Product: Pertuzumab+TRASTUZUMAB, ADJUVANT ENDOCRINE THERAPY
Description
This research study is studying a combination of HER2-directed therapies (trastuzumab and pertuzumab) and hormonal therapy as a treatment after surgery for hormone receptor positive breast cancer. The study drugs involved in this study are: * A combination of trastuzumab and pertuzumab given as an injection under the skin (PHESGO) * Hormonal (endocrine) Treatment
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer, Node Negative Breast Cancer, Micrometastasis Breast Cancer, Hormone Receptor Positive Breast Cancer
Study phase:
Phase II
Physician name:
Vicente Valero
Department:
Breast Medical Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.